Arrowstreet Capital Limited Partnership Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO

Arrowstreet Capital Limited Partnership cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,222,507 shares of the biopharmaceutical company’s stock after selling 68,158 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Halozyme Therapeutics were worth $216,875,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. DLD Asset Management LP increased its holdings in Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after purchasing an additional 5,000,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares during the last quarter. Norges Bank purchased a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. Finally, Federated Hermes Inc. increased its holdings in Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after purchasing an additional 123,917 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $69.50 on Monday. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The firm has a market capitalization of $8.24 billion, a P/E ratio of 25.00, a P/E/G ratio of 0.29 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The business has a 50 day simple moving average of $67.51 and a 200 day simple moving average of $68.72.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter in the previous year, the firm posted $1.11 EPS. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This trade represents a 3.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,250 shares of company stock valued at $6,299,746 in the last 90 days. Insiders own 2.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a report on Thursday, February 19th. UBS Group reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.